Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12145773 | 0.82 | NPSR1 (0.55) | NPSR1MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL9504950 | 0.79 | NPSR1 (0.53) | NPSR1MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL9865741 | 0.79 | HPGD (0.42) | NPSR1MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL8855482 | 0.77 | ALDH1A1 (0.41) | NPSR1MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL8855514 | 0.77 | ALDH1A1 (0.39) | NPSR1MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL1625968 | 0.75 | HCAR1 (0.33) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL9868847 | 0.74 | CSNK2A1 (0.47) | NPSR1MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL29176008 | 0.73 | NPSR1 (0.46) | NPSR1MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL3421751 | 0.72 | ALDH1A1 (0.47) | MAPTKDM4EALDH1A1HSD17B10CSNK2A1 | |
| SCHEMBL7045265 | 0.72 | HTR3E (0.47) | ALDH1A1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0845001-B1 | 5'-SUBSTITUTED-RIBOFURANOSYL BENZIMIDAZOLES AS ANTIVIRAL AGENTS | UNIV MICHIGAN (US) | 2002-11-13 | — | — | EP | claimed |
| US-5874413-A | CYTOMEGALO VIRUS | UNIVERSITY OF MICHIGAN (US) | 1999-02-23 | — | — | US | claimed |
| US-20030119762-A1 | 5'-substituted-ribofuranosyl benzimidazoles as antiviral agents | TOWNSEND LEROY B (US) | 2003-06-26 | — | — | US | disclosed |
| EP-0845001-B1 | 5'-SUBSTITUTED-RIBOFURANOSYL BENZIMIDAZOLES AS ANTIVIRAL AGENTS | UNIV MICHIGAN (US) | 2002-11-13 | — | — | EP | disclosed |
| US-6455506-B1 | Lyxofuranosyl benzimidazoles as antiviral agents | SMITHKLINE BEECHAM CORPORATION | 2002-09-24 | — | — | US | disclosed |
| US-20010011075-A1 | 5'-SUBSTITUTED-RIBOFURANOSYL BENZIMIDAZOLES AS ANTIVIRAL AGENTS | TOWNSEND LEROY B (US) | 2001-08-02 | — | — | US | disclosed |
| EP-1000080-A1 | LYXOFURANOSYL BENZIMIDAZOLES AS ANTIVIRAL AGENTS | The Regents of The University of Michigan (US) | 2000-05-17 | — | — | EP | disclosed |
| US-5874413-A | CYTOMEGALO VIRUS | UNIVERSITY OF MICHIGAN (US) | 1999-02-23 | — | — | US | disclosed |
| WO-1999006424-A1 | LYXOFURANOSYL BENZIMIDAZOLES AS ANTIVIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1999-02-11 | — | — | WO | disclosed |
| EP-0845001-A1 | 5'-SUBSTITUTED-RIBOFURANOSYL BENZIMIDAZOLES AS ANTIVIRAL AGENTS | The Regents of The University of Michigan (US) | 1998-06-03 | — | — | EP | disclosed |
| WO-1997007125-A1 | 5'-SUBSTITUTED-RIBOFURANOSYL BENZIMIDAZOLES AS ANTIVIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1997-02-27 | — | — | WO | disclosed |
| EP-0412211-A1 | Cancer therapy system | THERAPEUTICAL SYSTEMS CORPORATION (US) | 1991-02-13 | — | — | EP | disclosed |
| US-4935450-A | Cancer therapy system for effecting oncolysis of malignant neoplasms | THERAPEUTICAL SYSTEMS CORPORATION (US) | 1990-06-19 | — | — | US | disclosed |
| US-4724234-A | ADMINISTERING NUTRITIONAL REGIMEN AND AGENTS WHICH UNCOUPLE OXIDATIVE PHOSPHORYLATION | THERAPEUTICAL SYSTEMS CORP. (US) | 1988-02-09 | — | — | US | disclosed |
| US-4459238-A | N-Arylthiolcarbamates, herbicides containing them, and processes for combating the growth of unwanted plants with these compounds | BASF AKTIENGESELLSCHAFT (DE) | 1984-07-10 | — | — | US | disclosed |
| US-4122184-A | Benzimidazole insecticides | ELI LILLY AND COMPANY (US) | 1978-10-24 | — | — | US | disclosed |
| US-4029687-A | HERBICIDES | CIBA-GEIGY AG (CH) | 1977-06-14 | — | — | US | disclosed |
| US-4004914-A | HERBICIDES | CIBA-GEIGY AG (CH) | 1977-01-25 | — | — | US | disclosed |
| US-3951641-A | Use of N-(4-isopropoxy-3-chlorophenyl)-N'-methyl-N'-methoxyurea for control of weeds in maize cultures | CIBA-GEIGY AG (CH) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119762-A1 | 5'-substituted-ribofuranosyl benzimidazoles as antiviral agents | ZC3HAV1, ZC3HAV1L, IFNAR1 | NPSR1 4438/4885MAPT 4724/4885KDM4E 836/4885 |
| US-20010011075-A1 | 5'-SUBSTITUTED-RIBOFURANOSYL BENZIMIDAZOLES AS ANTIVIRAL AGENTS | ZC3HAV1, ZC3HAV1L, IFNAR1 | NPSR1 4438/4885MAPT 4724/4885KDM4E 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.